Aquatic Capital Management’s Viking Therapeutics VKTX Stock Holding History

Aquatic Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-94,275	Closed	-$3.32M	–	1840
2025 Q4	$3.32M	Buy	+94,275	New	+$3.34M	0.09%	262
2025 Q3	–	Sell	-163,712	Closed	-$4.34M	–	1700
2025 Q2	$4.34M	Buy	163,712 +85,268	+109%	+$2.24M	0.09%	272
2025 Q1	$1.89M	Sell	78,444 -130,690	-62%	-$4.13M	0.05%	428
2024 Q4	$8.42M	Buy	+209,134	New	+$11.9M	0.23%	112
2022 Q4	–	Sell	-14,300	Closed	-$39K	–	1863
2022 Q3	$39K	Buy	+14,300	New	+$46.8K	﹤0.01%	918
2022 Q2	–	Sell	-1,300	Closed	-$4K	–	1588
2022 Q1	$4K	Buy	+1,300	New	+$4.66K	0.01%	880

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Aquatic Capital Management's VKTX Position: Q1 2026 in Review

Aquatic Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 94,275 shares — an estimated $3.32M sold.

Aquatic Capital Management first reported a position in VKTX in Q1 2022 and held it in 6 quarters. The position peaked at $8.42M in Q4 2024. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Aquatic Capital Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Aquatic Capital Management sold 94,275 Viking Therapeutics shares in Q1 2026, an estimated $3.32M.
Aquatic Capital Management first reported a position in Viking Therapeutics in Q1 2022 and held it in 6 quarters.
Aquatic Capital Management's Viking Therapeutics position peaked at $8.42M in Q4 2024.
413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.